GlassScriptPhysician profile
Mark A Kleiner
NPI 1982610184
$14,752.62
in general payments reported to CMS, 2019-2025
56 companies · $1,759 in 2025
The $1,759 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,022 · 2020: $1,129 · 2021: $2,643 · 2022: $2,610 · 2023: $2,487 · 2024: $2,103 · 2025: $1,759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,334 · Entertainment: $14.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,333.99 |
| Entertainment | $14.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,949.37 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,947.63 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $1,701.39 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $770.37 | 2019-2025 | Jardiance |
| Pfizer INC. | $711.38 | 2019-2025 | |
| Abbott Laboratories | $640.82 | 2019-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $606.99 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $593.30 | 2019-2025 | Otezla, Repatha, Evenity |
| Glaxosmithkline, LLC. | $583.51 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Abbvie INC. | $526.45 | 2021-2025 | |
| Esperion Therapeutics, INC. | $426.24 | 2020-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $331.14 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $284.00 | 2020-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $273.17 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $239.04 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
Show all 52 companies
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Kleiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.